Floatz logo

Cediranib

Adult Acute Monoblastic Leukemia (M5a)

Bruno C. MedeirosSmall moleculePhase 3Active
BB
68/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
95/ 100

Competitive context

7 Active assets in the Adult Acute Monoblastic Leukemia (M5a) cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
Stanford University
Phase 3BBB
Cytosin-Arabinosid
Chinese PLA General Hospital
Phase 3BBB
Daunorubicin
National Cancer Institute (NCI)
Phase 3BBB
FILGRASTIM
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 3BBB
Mitoxantrone
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2/3BBB

View all 49 →

Same molecule, other indications

Cediranib is also rated in:

gliosarcomaDormant
BBB
Indicative ·
76 / 100
View asset →
Recurrent NeuroblastomaDormant
BBB
Indicative ·
73 / 100
View asset →
Recurrent Colon CancerDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →